This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta (SRPT) Sells Priority Review Voucher for $102M
by Zacks Equity Research
Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.
Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates
by Zacks Equity Research
Regulatory updates from Sarepta (SRPT) and Intercept (ICPT) are in focus in the biotech sector.
Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy
by Zacks Equity Research
Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.
FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8%
by Zacks Equity Research
FibroGen???s (FGEN) phase III study, evaluating pamrevlumab as a combination therapy in certain DMD patients, fails to meet its primary endpoint.
Mirati (MRTX) Down 17.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review
by Zacks Equity Research
The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.
Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates
by Zacks Equity Research
Regulatory and pipeline updates from Intercept (ICPT) and Sarepta (SRPT) lead to a decline in the share price of both companies.
Sarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel
by Zacks Equity Research
The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.